Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital raises questions about sustainable growth at Greggs

(Sharecast News) - Shore Capital has kept a 'hold' rating on Greggs after the bakery chain's interim figures showed "very challenging trading", raising questions about whether UK high streets have reached "peak Greggs". In the 26 weeks to 28 June, Greggs reported on Tuesday that pre-tax profit fell 14.3% to £63.5m, with total sales up 7% to £1.03bn. Operating profit declined to £70.4m from £75.8m in the same period a year earlier.

Like-for-like sales at company-managed shops rose 2.6%, while franchised shop LFL sales were ahead 4.8%.

Shore Capital said that, in the face of easing like-for-like sales momentum and with 2,600 stores and rising, Gregg's future investment thesis could be jeopardy from evolving dietary trends, such as the rise of appetite-suppressant drugs such as GLP-1 for high-calorie intake customers.

With certain customers increasingly cutting back on fast-food dining, and regular breakfast and lunchtime spending becoming costlier due to inflation, Shore Capital remains cautious.

"The volume performance of Greggs rightly or wrongly raises the question as to whether its core markets are evolving against the long-term interests of the firm, and/or whether or not the brand has reached its peak potency," Shore Capital said.

The broker forecasts "anaemic EPS growth" over 2024 to 2027, expecting the stock to "tread water over the short to medium term".

Shares were 3.6% lower at 1,586p by 1141 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.